PGT-A with Select Syndrome ScreenSM detects 10 impactful syndromes that standard PGT-A cannot — delivering deeper insights without adding complexity to your workflow.
Select Syndrome ScreenSM Helps to change that.
Powered by CooperSurgical’s exclusive PTA technology, this test analyzes smaller sections of DNA to identify impactful microdeletions and a microduplication, delivering a more comprehensive genetic profile with every PGT-A result.
What are microdeletions and microduplications?
Understanding the genetic changes that impact embryo viability or health and development after birth.
- Microdeletions: Small missing segments of DNA which can lead to developmental, cognitive, or medical challenges.
- Microduplications: Extra copies of DNA segments which may result in variable and sometimes unpredictable symptoms.
Syndromes detectable with Select Syndrome ScreenSM
Select Syndrome Screen SM includes 10 impactful genetic disorders that may significantly impact a child’s health or development.
Below is an overview of the 10 syndromes.
| Syndrome | Description | Genomic region | Estimated occurrence |
|---|---|---|---|
| DiGeorge syndrome (22q11.2 deletion syndrome/Velo-Cardio-Facial syndrome) | Affects heart, immune system, and development | 22q11.2 | 1 in 4,000 births |
| 1p36 deletion syndrome | Causes intellectual disability, seizures, and heart defects | 1p36 | 1 in 5,000 births |
| Wolf-Hirschhorn syndrome | Characterized by distinct facial features, seizures, and growth delays | 4p16.3 | 1 in 20,000 births |
| Cri du chat syndrome | Causes high-pitched cry in infancy, cognitive impairment | 5p15 | 1 in 20,000 births |
| Jacobsen syndrome | Leads to intellectual disability, heart defects, and bleeding disorders | 11q23-qter | 1 in 100,000 births |
| 2q33.1 deletion syndrome | Associated with speech delays, facial dysmorphisms, and feeding difficulties | 2q33.1 | Rarer, exact prevalence unknown |
| Potocki-Lupski/Smith-Magenis syndrome | A duplication syndrome linked to autism, hypotonia, and cardiac issues | 17p11.2 | 1 in 25,000 births |
| Smith-Magenis | Distinctive facial and physical features, mild-to-moderate intellectual disability, sleep and behavioral issues. Also variable vision, hearing, heart, and kidney issues. | 17p11.2 | 1 in 15,000 to 1 in 25,000 births |
| Langer-Giedion syndrome | Causes skeletal abnormalities, intellectual disability, and distinctive facial features | 8q23.1-q24.12 | 1 in 100,000 births |
| Angelman/Prader-Willi syndrome | Neurological and developmental disorders caused by imprinting errors on chromosome 15 | 15q11.2-q13.1 | 1 in 10,000–20,000 births |
Ready to Transform Your Genetic Screening?
For the Science Behind the Innovation
Discover how PTA and AI-driven analysis deliver new genetic insights.
The Profound Impact
Undetected microdeletions and duplications can profoundly affect a child’s lifelong health and may be associated with birth defects or developmental and intellectual disabilities.
Traditional methods do not screen for these conditions, leaving families unprepared for unexpected prenatal diagnoses. Select Syndrome ScreenSM detects these hidden risks early—before transfer—enabling proactive decision-making.
Every PGT-A Patient Will Benefit
Select Syndrome Screen isn’t just for high-risk cases—it’s for every patient undergoing PGT-A. Most microdeletions and microduplications are de novo events that can affect embryos from parents of any age, occurring spontaneously rather than being inherited.
When rare syndromes are detected before transfer, early education between patients and clinicians may provide better discussions on reproductive options and potential outcomes.
For Clinical Implementation
Learn how Select Syndrome Screen enhances patient care and streamlines your clinic’s genetic testing protocols.
For Patient Education
Access materials that help patients understand the benefits of enhanced genetic screening.
Ready to Get Started?
Connect with a CooperSurgical representative to discuss implementing Select Syndrome Screen in your clinic.
Ready to Transform Your Genetic Screening?
For the Science Behind the Innovation
Discover how PTA and AI-driven analysis deliver unprecedented genetic insights.
Download the White Paper
"*" indicates required fields